DUSP28 contributes to human hepatocellular carcinoma via regulation of the p38 MAPK signaling

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2596-2604

  Wang, Dong ^a   Han, Sheng ^a   Peng, Rui ^a   Jiao, Chenyu ^a   Wang, Xing ^a   Han, Zeguang ^b   Li, Xiangcheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Cancer therapy; Cell proliferation; Dual specificity phosphatase 28; G1 s transition; Hepatocellular carcinoma; P38

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; DUSP26 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; SMALL INTERFERING RNA;

BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DUAL-SPECIFICITY PHOSPHATASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84907693417     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2653     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011.
2. Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (review). Int J Oncol 42:1133-1138, 2013.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538, 2006.
4. Yang Y, Nagano H, Ota H, et al: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 141:196-202, 2007.
5. Hwang S, Moon DB and Lee SG: Liver transplantation and conventional surgery for advanced hepatocellular carcinoma. Transplant Int 23:723-727, 2010.
6. Abdel-Wahab M, Sultan AM, Fathy OM, et al: Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 60:1847-1853, 2013.
7. Sandhu DS, Baichoo E and Roberts LR: Fibroblast growth factor signaling in liver carcinogenesis. Hepatology 59:1166-1173, 2014.
8. Guegan JP, Ezan F, Theret N, Langouet S and Baffet G: MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells. Carcinogenesis 34:38-47, 2013.
9. Fuchs BC, Hoshida Y, Fujii T, et al: Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59:1577-1590, 2014.
10. Gao W, Kim H, Feng M, et al: Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 60:576-587, 2014.
11. Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290, 2007.
12. Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396-405, 2010.
13. Jeong DG, Wei CH, Ku B, et al: The family-wide structure and function of human dual-specificity protein phosphatases. Acta Crystallogr D Biol Crystallogr 70:421-435, 2014.
14. Wu GS: Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 26:579-585, 2007.
15. Keyse SM: Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27:253-261, 2008.
16. Haagenson KK and Wu GS: Mitogen activated protein kinase phosphatases and cancer. Cancer Biol Ther 9:337-340, 2010.
17. Haagenson KK and Wu GS: The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 29:143-149, 2010.
18. Sekine Y, Tsuji S, Ikeda O, et al: Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene 25:5801-5806, 2006.
19. Sekine Y, Ikeda O, Hayakawa Y, et al: DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene 26:6038-6049, 2007.
20. Li JP, Fu YN, Chen YR and Tan TH: JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration. J Biol Chem 285:5472-5478, 2010.
21. Rahmouni S, Cerignoli F, Alonso A, et al: Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol 8:524-531, 2006.
22. Shang X, Vasudevan SA, Yu Y, et al: Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene 29:4938-4946, 2010.
23. Klinger S, Poussin C, Debril MB, Dolci W, Halban PA and Thorens B: Increasing GLP-l-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes 57:584-593, 2008.
24. Patterson KI, Brummer T, O'Brien PM and Daly RJ: Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475-489, 2009.
25. Prabhakar S, Asuthkar S, Lee W, et al: Targeting DUSPs in glioblastomas - wielding a double-edged sword? Cell Biol Int 38:145-153, 2014.
26. Nunes-Xavier C, Roma-Mateo C, Rios P, et al: Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 11:109-132, 2011.
27. Rios P, Nunes-Xavier CE, Tabernero L, Kohn M and Pulido R: Dual-specificity phosphatases as molecular targets for inhibition in human disease. Antioxid Redox Signal 20:2251-2273, 2014.
28. Thornton TM and Rincon M: Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci 5:44-51, 2009.
29. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537-549, 2009.
30. Ayub A, Ashfaq UA and Haque A: HBV induced HCC: major risk factors from genetic to molecular level. Biomed Res Int 2013:810461, 2013.
31. Arnoldussen YJ, Lorenzo PI, Pretorius ME, et al: The mitogenactivated protein kinase phosphatase vaccinia Hl-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res 68:9255-9264, 2008.
32. Henkens R, Delvenne P, Arafa M, et al: Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC cancer 8:147, 2008.
33. Tang JP, Tan CP, Li J, et al: VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers. Mol Cancer 9:128, 2010.
34. Deng Q, Li KY, Chen H, et al: RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma. Hepatology 59:518-530, 2014.
35. Bai L, Yoon SO, King PD and Merchant JL: ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ 11:663-673, 2004.
36. Yu W, Imoto I, Inoue J, Onda M, Emi M and Inazawa J: A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26:1178-1187, 2007.
37. Bertoli C, Skotheim JM and de Bruin RA: Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 14:518-528, 2013.
38. Hui L, Bakiri L, Mairhorfer A, et al: p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun. pathway. Nat Genet 39:741-749, 2007.
39. Hui L, Bakiri L, Stepniak E and Wagner EF: p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6:2429-2433, 2007.